摘要
本研究主要探讨孕激素受体(PR)对雌激素受体阳性(ER+)和人表皮生长因子受体2(HER-2)阴性晚期乳腺癌患者接受芳香化酶抑制剂(AI)治疗的疗效及无疾病进展时间(PFS)的影响。收集2014年1月至2019年10月河南省肿瘤医院收治的198例晚期乳腺癌患者[均为女性,年龄50(27,80)岁]的临床资料,采用χ^(2)检验对比生存的差异;应用Cox回归模型分析相关预后因素。结果显示,PR+、PR-患者的中位PFS分别为12.5个月和9.0个月,两组生存差异有统计学意义(P=0.004);临床获益(CBR)分别为81.1%和63.1%,差异有统计学意义(P<0.001)。PR+乳腺癌患者的PFS较PR-型乳腺癌患者长,差异有统计学意义(P<0.001)。提示PR是ER+及HER-2阴性患者一线芳AI内分泌治疗的独立预后因素,PR+型较PR-型晚期乳腺癌对一线AI内分泌治疗反应好,PFS时间更长。
To investigate the effect of progesterone receptor(PR)on the efficacy of first-line aromatase inhibitor(AI)endocrine therapy and progression-free survival(PFS)in patients with estrogen receptor(ER)positive HER-2 negative advanced breast cancer.The clinical data of 198 patients with advanced breast cancer treated in Henan Cancer Hospital from January 2014 to October 2019 were collected.The Chi-square test was used to compare the difference between the two groups,and the Cox regression model was used to analyze the related prognostic factors.The median progression-free survival time((PFS))of PR+and PR-patients were 12.5 months and 9.0 months,respectively,and the difference was statistically significant(P=0.004).The clinical benefit rate(CBR)was 81.1%and 63.1%,respectively,and the difference was not statistically significant(P<0.001).PR is an independent prognostic factor of first-line AI endocrine therapy in ER-positive HER-2-negative patients.PR+type breast cancer has a better response to first-line AI endocrine therapy and longer PFS time than PR-type advanced breast cancer.
作者
张梦玮
律慧敏
牛李敏
曾惠爱
闫敏
Zhang Mengwei;Lyu Huimin;Niu Limin;Zeng Huiai;Yan Min(Department of Breast 7 of Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou 450000,China)
出处
《中华医学杂志》
CAS
CSCD
北大核心
2022年第10期741-744,共4页
National Medical Journal of China
关键词
孕激素受体
雌激素受体
芳香化酶抑制剂
疗效
Progesterone receptor
Estrogen receptor
Aromatase inhibitor
Efficacy